RF
NBIX icon

Rossby Financial’s Neurocrine Biosciences NBIX Stock Holding History

Rossby Financial’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.15K Buy
69
+42
+156% +$5.57K ﹤0.01% 1290
2025
Q4 		$3.83K Buy
27
+10
+59% +$1.45K ﹤0.01% 1194
2025
Q3 		$2.33K Buy
+17
New +$2.3K ﹤0.01% 1118

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rossby Financial's NBIX Position: Q1 2026 in Review

Rossby Financial increased its Neurocrine Biosciences (NBIX) stake by 156% in Q1 2026, buying an estimated $5.57K and bringing the position to 69 shares worth $9.15K. The position accounts for ﹤0.01% of the portfolio, ranked #1290.

Rossby Financial first reported a position in NBIX in Q3 2025 and has held it in 3 quarters since. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Rossby Financial held 69 shares of Neurocrine Biosciences worth $9.15K as of Q1 2026.
  • Rossby Financial bought 42 Neurocrine Biosciences shares in Q1 2026, an estimated $5.57K.
  • Neurocrine Biosciences made up ﹤0.01% of Rossby Financial's portfolio in Q1 2026, its #1290 holding.
  • Rossby Financial first reported a position in Neurocrine Biosciences in Q3 2025 and has held it in 3 quarters since.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Rossby Financial's 13F filing for Q1 2026, filed 11 May 2026.